{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:50:48Z","timestamp":1784857848495,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"DOI":"10.7759\/cureus.62407","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:28:52Z","timestamp":1718422132000},"source":"Crossref","is-referenced-by-count":2,"title":["A Rare Case of Hemophilia: Acquired Factor VIII Deficiency"],"prefix":"10.7759","author":[{"given":"Soe P","family":"Winn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fizza","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Peeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"A survey of 215 non-hemophilic patients with inhibitors to factor VIII","volume":"45","author":"Green D","year":"1981","unstructured":"Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981, 45:200-3.","journal-title":"Thromb Haemost"},{"key":"ref2","article-title":"The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study","volume":"78","author":"Hay CR","year":"1997","unstructured":"Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost. 1997, 78:1463-7.","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.22.7728","article-title":"Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments","volume":"82","author":"Fulcher CA","year":"1985","unstructured":"Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A. 1985, 82:7728-32. 10.1073\/pnas.82.22.7728","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.42.29826","article-title":"Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa","volume":"274","author":"Fay PJ","year":"1999","unstructured":"Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem. 1999, 274:29826-30. 10.1074\/jbc.274.42.29826","journal-title":"J Biol Chem"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V60.5.1103.1103","article-title":"Inactivation of factor VIII coagulant activity by two different types of human antibodies","volume":"60","author":"Gawryl MS","year":"1982","unstructured":"Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982, 60:1103-9.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000056708","article-title":"Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies","volume":"77","author":"Scandella D","year":"1999","unstructured":"Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang. 1999, 77:17-20. 10.1159\/000056708","journal-title":"Vox Sang"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08890.x","article-title":"Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?","volume":"156","author":"Mahendra A","year":"2012","unstructured":"Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?. Br J Haematol. 2012, 156:3-12. 10.1111\/j.1365-2141.2011.08890.x","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.432","article-title":"Acquired factor VIII inhibitors: pathophysiology and treatment","author":"Ma AD","year":"2006","unstructured":"Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006, 432-7. 10.1182\/asheducation-2006.1.432","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04731.x","article-title":"A population based, unselected, consecutive cohort of patients with acquired haemophilia A","volume":"124","author":"Collins P","year":"2004","unstructured":"Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2004, 124:86-90. 10.1046\/j.1365-2141.2003.04731.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"Collins PW","year":"2007","unstructured":"Collins PW, Hirsch S, Baglin TP, et al.. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007, 109:1870-7. 10.1182\/blood-2006-06-029850","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14632","article-title":"Immune checkpoint inhibitor-induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"28","author":"Moore DC","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN. Immune checkpoint inhibitor-induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia. 2022, 28:e145-8. 10.1111\/hae.14632","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova A","year":"2009","unstructured":"Pavlova A, Delev D, Lacroix-Desmazes S, et al.. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009, 7:2006-15. 10.1111\/j.1538-7836.2009.03636.x","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres R","year":"2017","unstructured":"Kruse-Jarres R, Kempton CL, Baudo F, et al.. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017, 92:695-705. 10.1002\/ajh.24777","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13499","article-title":"Diagnostic delay in acquired haemophilia: analysis of causes and consequences in a 20-year Spanish cohort","volume":"24","author":"Pardos-Gea J","year":"2018","unstructured":"Pardos-Gea J, Fern\u00e1ndez-D\u00edaz N, Parra R, Cortina V, Altisent C. Diagnostic delay in acquired haemophilia: analysis of causes and consequences in a 20-year Spanish cohort. Haemophilia. 2018, 24:e163-6. 10.1111\/hae.13499","journal-title":"Haemophilia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S284804","article-title":"Acquired hemophilia A: current guidance and experience from clinical practice","volume":"13","author":"Pishko AM","year":"2022","unstructured":"Pishko AM, Doshi BS. Acquired hemophilia A: current guidance and experience from clinical practice. J Blood Med. 2022, 13:255-65. 10.2147\/JBM.S284804","journal-title":"J Blood Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede A","year":"2020","unstructured":"Tiede A, Collins P, Knoebl P, et al.. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020, 105:1791-801. 10.3324\/haematol.2019.230771","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede A","year":"2015","unstructured":"Tiede A, Klamroth R, Scharf RE, et al.. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study. Blood. 2015, 125:1091-7. 10.1182\/blood-2014-07-587089","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon B","year":"2022","unstructured":"Simon B, Cegl\u00e9di A, Dolgos J, et al.. Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen. Blood. 2022, 140:1983-92. 10.1182\/blood.2022016873","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04345.x","article-title":"Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia","volume":"9","author":"Boles JC","year":"2011","unstructured":"Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost. 2011, 9:1429-31. 10.1111\/j.1538-7836.2011.04345.x","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01342.x","article-title":"Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy","volume":"13","author":"Field JJ","year":"2007","unstructured":"Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007, 13:46-50. 10.1111\/j.1365-2516.2006.01342.x","journal-title":"Haemophilia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"L\u00e9vesque H","year":"2024","unstructured":"L\u00e9vesque H, Viallard JF, Houivet E, et al.. Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients. Thromb Res. 2024, 237:79-87. 10.1016\/j.thromres.2024.03.012","journal-title":"Thromb Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13658","article-title":"Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A","volume":"25","author":"Obaji S","year":"2019","unstructured":"Obaji S, Rayment R, Collins PW. Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia. 2019, 25:e59-65. 10.1111\/hae.13658","journal-title":"Haemophilia"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1811","article-title":"Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept","volume":"105","author":"Zeitler H","year":"2005","unstructured":"Zeitler H, Ulrich-Merzenich G, Hess L, et al.. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005, 105:2287-93. 10.1182\/blood-2004-05-1811","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253377-a-rare-case-of-hemophilia-acquired-factor-viii-deficiency","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:28:56Z","timestamp":1718422136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253377-a-rare-case-of-hemophilia-acquired-factor-viii-deficiency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.62407","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}